How genetic differences affect leflunomide response in Pakistani rheumatoid arthritis patients
Official title: Pharmacogenetics of Leflunomide in the RA Management
Run by Foundation University Islamabad · NCT07388407 · Data updated 2026-11-12
This project will test whether specific genetic variants (SNPs) predict how well leflunomide works and whether it causes side effects in Pakistani adults with rheumatoid arthritis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 65 Years |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Foundation University Islamabad Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 2 sites (Islamabad, Punjab Province and 1 other locations) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT07388407 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20–75 of Pakistani origin with rheumatoid arthritis who are starting leflunomide as the sole DMARD (with or without steroids), can consent, and can provide blood samples are the intended participants.
✕Probably not a fit
People who are not Pakistani, are taking other DMARDs, have significant renal or liver impairment, are pregnant or lactating, have active infections, or cannot complete three months of leflunomide therapy are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will enroll Pakistani adults with rheumatoid arthritis who are starting leflunomide as their only DMARD or have been on it for less than a month. Participants will give a blood sample for DNA extraction and be followed across two visits three months apart while clinicians record disease activity (DAS28), ultrasound findings, and laboratory markers including ESR, CRP, anti-CCP, and liver tests. SNPs will be identified in the laboratory and correlated with measures of efficacy and toxicity using the collected clinical and biochemical data. The investigators plan to use these correlations to build an algorithm tailored to Pakistani RA patients to help guide leflunomide use.
Why it matters
Potential benefit: If successful, this work could help doctors predict which patients are likely to benefit from leflunomide and which are at higher risk of side effects, enabling more personalized treatment.
How similar studies have gone: Pharmacogenetic work on leflunomide and related drugs has reported some SNP associations with drug levels and toxicity but findings are limited and not yet definitive or widely implemented.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10 * Pakistani individuals * between ages of 20-75 years * New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available Exclusion Criteria: * Patients not willing to participate/ consent not given * Patients below the age of 20 * Non- Pakistani origin * Taking another DMARD simultaneously * Compromised renal and hepatic functions * Cognitive impairment, neurological disease * Pregnant/ lactating patients * Patients having inflammatory bowel disease/ Irritable bowel syndrome * Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-
Where it's running
-
Fauji Foundation Hospital, Rawalpindi
Rawalpindi, Punjab Province, Pakistan Recruiting -
Shifa International Hospital
Islamabad, Punjab Province, Pakistan Completed
Study contacts
- Study coordinator: Dr. Zarafshan Bader, MPhil, MBBS
- Email: zarafshan.bader@fui.edu.pk
- Phone: 0923005177254
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tornier Perform Reversed MonoPost Shoulder Implant: Patient Follow-Up in Real World Care
This study tests how well the Tornier Perform Reversed MonoPost shoulder implant works in adults with shoulder problems over two years by following patients after surgery at multiple centers.
-
JADE201: a first-in-human test for rheumatoid arthritis
This first-in-human study tests a single dose of JADE201 versus placebo to see if it is safe and how it behaves in people with rheumatoid arthritis.
-
SLE Registry in Pakistan to understand how lupus presents and progresses
This project is building a Pakistan lupus registry to see how SLE shows up and changes over time in adults, starting at Fauji Foundation Hospital Rawalpindi.
-
Effects of Instrument-Assisted Soft Tissue Mobilization vs Post Facilitation Stretch in Chronic Neck Pain
This trial compares two manual therapy techniques, IASTM and Post Facilitation Stretch, to see which better reduces neck pain and improves movement and function in adults with chronic neck pain.
-
Mulligan leg raise vs spinal mobilization with leg movement for lumbar radiculopathy
This trial tests whether Mulligan leg raise traction or spinal mobilization with leg movement helps people with lumbar radiculopathy feel better.
-
Flutter therapy added to chest physiotherapy after CABG in COPD patients
This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.